Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ocumension Acquires Implant Therapy for Retina Diseases in $119 Million Deal

publication date: Apr 14, 2021

Shanghai Ocumension Therapeutics acquired Greater China rights to Alimera’s implant therapy for diabetic macular edema and other retina diseases in a $119 million agreement. Alimera is an Atlanta area company. Ocumension will develop Iluvien® 0.19mg fluocinolone acetonide intravitreal implant for use in Greater China. It made a $10 million equity investment in Alimera, paid $10 million upfront and will be responsible for up to $89 million in sales-based milestones. Ocumension will will also issue four-year warrants for 1 million of its shares to Alimera. More details....

Stock Symbol: (HK: 1477)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here